MedTrace Logo

Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction

NCT02544087 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2017-07-31

No results posted yet for this study

Summary

The present study is designed to confirm the therapeutic effects of heat-clearing and blood-activating Chinese medicinal components in treatment of Acute Cerebral Infarction (ACI) and to investigate the therapeutic mechanisms of multi-target anti-inflammatory action involved from the standpoint of pathology, cell and molecular biology, as well as immunology.

Conditions

Interventions

DRUG

Ixeris of sonchifolia Hance

KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.

DRUG

Panax notoginseng saponins

Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.

DRUG

Ixeris of sonchifolia Hance combined with Panax notoginseng saponins

KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.

Sponsors & Collaborators

  • Shandong University of Traditional Chinese Medicine

    collaborator OTHER

  • Huairou Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Yunling Zhang

    lead OTHER

Principal Investigators

  • Yunling Zhang, PhD,MD · Dongfang Hospital Beijing University of Chinese Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02544087 on ClinicalTrials.gov